Medicines Safety: Roche's Tecentriq has become the fourth checkpoint
inhibitor caught up in the aftermath of trial deaths involving blockbuster biologic
Keytruda, with the FDA now considering a class-wide safety alert.
Treatment Trends: AstraZeneca's type 2 diabetes drug
failed to show it reduced adverse cardiovascular events indicating that not all
drugs in the GLP-1 class confer the prevention benefit.
Queue for PBS listing stretches back years
With drugs waiting in the wings for PBS listing more than two and a half years after being recommended, the road to reimbursement remains a long and winding one and for some, it's a road to nowhere.